Guidance on the Selection of Appropriate Indicators for Quantification of Antimicrobial Usage in Humans and Animals by Collineau, L et al.
  
RVC OPEN ACCESS REPOSITORY – COPYRIGHT NOTICE 
 
This is the peer reviewed version of the following article: 
Collineau, L., Belloc, C., Stärk, K. D. C., Hémonic, A., Postma, M., Dewulf, J. and Chauvin, 
C. (2016), Guidance on the Selection of Appropriate Indicators for Quantification of 
Antimicrobial Usage in Humans and Animals. Zoonoses Public Health. 
doi:10.1111/zph.12298 
This article may be used for non-commercial purposes in accordance with Wiley Terms and 
Conditions for Self-Archiving. 
The full details of the published version of the article are as follows: 
 
TITLE: Guidance on the Selection of Appropriate Indicators for Quantification of 
Antimicrobial Usage in Humans and Animals 
AUTHORS: Collineau, L., Belloc, C., Stärk, K. D. C., Hémonic, A., Postma, M., Dewulf, J. 
and Chauvin, C.  
JOURNAL TITLE: Zoonoses Public Health  
PUBLISHER: Wiley 
PUBLICATION DATE: 4 September 2016 (online) 
DOI: 10.1111/zph.12298 
1 
 
Running head: Guidance on the selection of antimicrobial usage indicators 1 
 2 
Guidance on the selection of appropriate indicators for quantification 3 
of antimicrobial usage in humans and animals 4 
Lucie Collineau1, 2*, Catherine Belloc2, Katharina D.C. Stärk1, Anne Hémonic3, Merel Postma4, 5 
Jeroen Dewulf4, Claire Chauvin5 6 
1 SAFOSO AG, Bern Liebefeld, Switzerland  7 
2 BIOEPAR, INRA, Oniris, La Chantrerie, 44307, Nantes, France 8 
3 IFIP – French Pork and Pig Institute, Le Rheu, France 9 
4 Ghent University, Faculty of Veterinary Medicine, Department of Reproduction, Obstetrics and 10 
Herd Health, Veterinary Epidemiology Unit, Ghent, Belgium 11 
5 Anses – French Agency for Food, Environmental and Occupational Health and Safety, 12 
Ploufragan, France 13 
 14 
Corresponding author:  15 
SAFOSO AG, Waldeggstrasse 1, CH 3097 Liebefeld, Switzerland 16 
Phone: +41 31 544 25 04; Fax: +41 31 544 25 01 17 
E-mail: lucie.collineau@safoso.ch 18 
  19 
2 
 
Impacts 20 
 Various indicators are available to quantify antimicrobial usage from sales, deliveries or 21 
reimbursement data in human and veterinary medicine; results can differ substantially 22 
depending on the method used 23 
 To select the most appropriate indicators of antimicrobial usage, the study objective must 24 
first be determined; if the overall aim is to compare antimicrobial usage between 25 
populations, standardised parameters should be used, whereas the quantification of 26 
exposure to antimicrobials should rely on actual parameters 27 
 Major gaps such as the absence of a gold standard for evaluating indicators and the lack 28 
of a scientific basis to assess antimicrobial selection pressure hamper the identification of 29 
the most suitable indicator for a given study objective 30 
 31 
Summary 32 
An increasing variety of indicators of antimicrobial usage has become available in human and 33 
veterinary medicine, with no consensus on the most appropriate indicators to be used. The 34 
objective of this review is therefore to provide guidance on the selection of indicators, intended 35 
for those aiming to quantify antimicrobial usage based on sales, deliveries or reimbursement data.  36 
Depending on the study objective, different requirements apply to antimicrobial usage 37 
quantification in terms of resolution, comprehensiveness, stability over time, ability to assess 38 
exposure and comparability. If the aim is to monitor antimicrobial usage trends, it is crucial to use 39 
a robust quantification system that allows stability over time in terms of required data and provided 40 
output; to compare usage between different species or countries, comparability must be ensured 41 
between the different populations. If data are used for benchmarking, the system 42 
comprehensiveness is particularly crucial, while data collected to study the association between 43 
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usage and resistance should express the exposure level and duration as a measurement of the 44 
exerted selection pressure. 45 
Antimicrobial usage is generally described as the number of technical units consumed normalised 46 
by the population at risk of being treated in a defined period. The technical units vary from number 47 
of packages to number of individuals treated daily by adding different levels of complexity such 48 
as daily dose or weight at treatment.  These technical units are then related to a description of 49 
the population at risk, based either on biomass or number of individuals. Conventions and 50 
assumptions are needed for all of these calculation steps. However, there is a clear lack of 51 
standardisation, resulting in poor transparency and comparability. By combining study 52 
requirements with available approaches to quantify antimicrobial usage, we provide suggestions 53 
on the most appropriate indicators and data sources to be used for a given study objective. 54 
 55 
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Introduction 59 
Antimicrobial products (antimicrobials) have been used widely and successfully for the treatment 60 
and prevention of infectious diseases in humans and animals. However, the optimism of the early 61 
period of antimicrobial discovery has been tempered by the emergence of bacterial strains 62 
resistant to these therapeutics (Levy and Marshall, 2004) that have a serious clinical impact on 63 
human (Collignon, 2012) and animal health (Vaarten, 2012). An increasing number of studies 64 
have shown that antimicrobial usage in humans (Charbonneau et al., 2006; Costelloe et al., 2010; 65 
Sun et al., 2012) and animals (Burow et al., 2013; Hammerum et al., 2014; Simoneit et al., 2015) 66 
is the main driver for the development of antimicrobial resistance. 67 
As a consequence, international organisations have encouraged the collection of antimicrobial 68 
usage data in order to manage and minimise the further development of antimicrobial resistance 69 
(World Health Organization, 2013; World Organisation for Animal Health, 2015a). In this article, 70 
antimicrobial usage refers to the exposure of a given individual or group over a certain period of 71 
time to a certain amount of antimicrobial active substance. The collection of antimicrobial usage 72 
data includes both monitoring, i.e. the routine collection of information on antimicrobial usage 73 
(Thrusfield, 2013), and punctual data collection from the whole population or from a representative 74 
sample of the national population. The data collected can be quantitative only (i.e. amounts of 75 
antimicrobials) or include a qualitative description of usage (describing, for example, treatment 76 
indication, antimicrobial class, active substance and route of administration). Quantification is 77 
based on ‘indicators’ of antimicrobial usage, defined as the number of ‘technical’ units of 78 
measurement (i.e. the amount of antimicrobials) consumed and normalised by the population at 79 
risk of being treated in a defined period (European Medicines Agency, 2013).  80 
An increasing variety of indicators of antimicrobial usage has become available in human and 81 
animal medicine but none has been put forward as the most appropriate to measure antimicrobial 82 
usage. The main difficulties encountered when trying to identify suitable indicators are related to 83 
i) the number of different antimicrobial usage indicators available in both human (Coenen et al., 84 
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2014; Fortin et al., 2014) and veterinary medicine (Chauvin et al., 2001), ii) the apparent 85 
discrepancies or contradictions between the results obtained from different indicators applied to 86 
the same antimicrobial usage data (Chauvin et al., 2001; Polk et al., 2007; Dalton et al., 2007; 87 
Chauvin et al., 2008; Bruyndonckx et al., 2014), and iii) the diversity of interests, perceived utility 88 
and needs among the stakeholders involved in the collection of antimicrobial usage data 89 
(DeVincent and Viola, 2006; Benedict et al., 2012). Indeed, a range of study objectives can be 90 
pursued with the collection of antimicrobial usage data. As has been shown for the monitoring of 91 
antimicrobial resistance (Lewis, 2002; Hunter and Reeves, 2002) and for disease surveillance in 92 
general (Thrusfield, 2013), the study objective should be clearly stated at an early stage of study 93 
design in order for a monitoring or surveillance system to be successful. However, most studies 94 
do not provide a clear rationale for the selection of a certain indicator and data source to measure 95 
antimicrobial usage. 96 
Consequently, the objective of this review article is to provide guidance to select the most suitable 97 
indicators of antimicrobial usage and data sources in accordance with a specific study objective. 98 
Indicators from both veterinary and human medicine are included for two reasons: i) some of the 99 
difficulties associated with the quantification of antimicrobial usage are common to both 100 
disciplines; each discipline can therefore benefit from the experience gained in the other, and ii) 101 
in a One Health context, barriers between the disciplines should be lowered as it becomes critical 102 
to develop a common approach to measure antimicrobial usage in humans and animals (ECDC, 103 
EFSA and EMA, 2015). The review is structured as follows: first, the principal objectives of 104 
measuring antimicrobial usage in humans and animals are described, and, for each objective, the 105 
main requirements regarding the way in which antimicrobial usage data should be measured are 106 
identified. Next, available indicators of antimicrobial usage in human and veterinary medicine are 107 
presented and compared, focusing on those calculated from antimicrobial sales, deliveries and 108 
reimbursement data. Finally, suggestions are provided to select the most suitable indicators of 109 
antimicrobial usage and data sources in accordance with the study objective. A glossary of 110 
abbreviations used in this article is available in Appendix S1 of the article supporting information. 111 
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 112 
Why measure antimicrobial usage? 113 
The collection of antimicrobial usage data serves four main objectives. First, antimicrobial usage 114 
is measured for the monitoring of antimicrobial usage trends over time (Objective 1). A number 115 
of countries report annual antimicrobial usage data that are compared to the usage observed in 116 
previous years. Reports on antimicrobial usage are communicated either separately for human 117 
medicine (Petrov et al., 2005; Mölstad et al., 2008; Meyer et al., 2013; Health Protection Scotland, 118 
2014; Australia Infection Control Service, 2014) and veterinary medicine (Ministry of Agriculture, 119 
Forestry and Fisheries of Japan, 2013; Federal Agency for Medicines and Health Products, 2013; 120 
Veterinary Medicines Directorate, 2013; Food and Drug Administration, 2014; Anses, 2014) or in 121 
a joint report (NORM and NORM-VET, 2012; Public Health Agency of Canada, 2013). European 122 
countries also report their antimicrobial usage trends over time in a joint report and using a 123 
standardised approach between countries. This work is conducted by the European Surveillance 124 
of Antimicrobial Consumption Network (ESAC-Net) for antimicrobial usage in humans (Vander 125 
Stichele et al., 2004; Adriaenssens et al., 2011) and by the European Surveillance of Veterinary 126 
Antimicrobial Consumption (ESVAC) project for veterinary antimicrobial usage (European 127 
Medicines Agency, 2014). 128 
Antimicrobial usage monitoring over time makes it possible more specifically to quantify the 129 
impact of control strategies or intervention programmes. Examples include the assessment of the 130 
effect of the European Union (EU) ban on antimicrobials as animal growth promotors initiated by 131 
Sweden in 1986 (Wierup, 2001; Casewell et al., 2003; Aarestrup et al., 2010) or the assessment 132 
of the impact of antimicrobial awareness campaigns (Huttner et al., 2010). While most of the 133 
evaluations of intervention programmes aim at quantifying the reduction in the amount of 134 
antimicrobials used, some also assess qualitatively the evolution of antimicrobial treatment 135 
practices, for example assessing medical doctors’ compliance with guidelines on good 136 
antimicrobial prescription practices (Ashiru-Oredope et al., 2012). Because the need for 137 
antimicrobial treatments is closely related to the disease situation, the monitoring of antimicrobial 138 
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usage over time can also provide useful information on the temporal evolution of the health 139 
situation, for example following the introduction of new vaccines or the emergence of new 140 
diseases, e.g. the chronic wasting disease in pigs that emerged in Europe in the 1990s (Jensen 141 
et al., 2012). 142 
Antimicrobial usage data also commonly serve to compare antimicrobial usage between different 143 
populations, for example different animal species populations (Veterinary Medicines Directorate, 144 
2013; DANMAP, 2013; NETHMAP and MARAN, 2013), human and animal populations (ECDC, 145 
EFSA and EMA, 2015) or different countries (Goossens et al. 2007; Elseviers et al., 2007; Grave 146 
et al., 2010) (Objective 2). In addition, ‘benchmarking’ systems were implemented at hospital, 147 
outpatient clinic or farm level, with the objective of identifying high antimicrobial users and thus 148 
promoting the reduction or more prudent usage of antimicrobials relying on a sort of ‘shame effect’ 149 
on heavy users (Jacquet et al., 2011) (Objective 3). Such programmes were for example 150 
implemented in the USA and Germany to compare antimicrobial usage between the intensive 151 
care units of different hospitals (Fridkin et al., 1999; Meyer et al., 2013). Benchmarking between 152 
farms has also been routinely implemented nationwide in Denmark (Danish Veterinary and Food 153 
Administration, 2011) and in the Netherlands (Bos et al., 2013).  154 
The monitoring of antimicrobial usage also provides useful data to study the association between 155 
antimicrobial usage and resistance (Objective 4), i.e. to describe how the exposure of humans 156 
and animals to antimicrobial treatments relates to the selection of resistant bacteria or genes and 157 
to their spread between different epidemiological units (including farms, hospitals or the 158 
environment). Several ecological studies conducted at national and European level showed a 159 
significant association between national and European aggregated amounts of antimicrobial sales 160 
and antimicrobial resistance prevalence (ECDC, EFSA and EMA, 2015), in both human 161 
(Goossens et al., 2005; van de Sande-Bruinsma et al., 2008) and veterinary medicine 162 
(Chantziaras et al., 2014; Garcia-Migura et al., 2014). Other studies also quantified the 163 
association between antimicrobial usage and resistance at farm level (Akwar et al., 2008; 164 
Persoons et al., 2011; Agga et al., 2014) or hospital level (Charbonneau et al., 2006). Some 165 
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studies demonstrated that the development and spread of antimicrobial resistance was related to 166 
certain antimicrobial treatment practices, including the choice of a particular administration route 167 
(Varga et al., 2009; Burow et al., 2013; Simoneit et al., 2015), use of a specific antimicrobial class, 168 
e.g. fluoroquinolone (Taylor et al., 2009), treatment duration (D’Agata et al., 2007) and number of 169 
treatment courses (Costelloe et al., 2010).  170 
 171 
For each study objective, what are the requirements regarding the 172 
measurement of antimicrobial usage? 173 
The study objective entails certain requirements regarding the measurement of antimicrobial 174 
usage; these are grouped into five categories: level of resolution, comprehensiveness, stability of 175 
the measure over time, ability to assess exposure to antimicrobials, and comparability of the 176 
measure between different populations (Table 1).  177 
[Insert Table 1] 178 
Spatial and temporal resolution 179 
The level of resolution includes both a spatial and temporal component. The level of spatial 180 
resolution relates to where antimicrobial usage is observed; this can be at supra-national level 181 
(Wirtz et al., 2010; Adriaenssens et al., 2011; European Medicines Agency, 2014 ; Versporten et 182 
al., 2014), national level (Achermann et al., 2011; Bondt et al., 2011; Suda et al., 2014), farm level 183 
(Chauvin et al., 2008; Callens et al., 2012; Pardon et al., 2012; Persoons et al., 2012) or hospital 184 
and outpatient clinic level (Arnold et al., 2006; Dumartin et al., 2010). While low spatial resolution 185 
is sufficient to compare antimicrobial usage between different species or countries, high resolution 186 
is required to compare antimicrobial usage between farms, hospitals or outpatient clinics (i.e. the 187 
resolution level should be equal to or higher than the level of the units that are compared). For 188 
studies exploring the association between antimicrobial usage and resistance, low resolution level 189 
data has been used to quantify the association between antimicrobial usage and level of 190 
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occurrence of resistant bacteria and strains, which includes both the selection and spread of 191 
antimicrobial resistance (van de Sande-Bruinsma et al., 2008; Chantziaras et al., 2014; Garcia-192 
Migura et al., 2014; ECDC, EFSA and EMA, 2015). On the other hand, studies conducted at high 193 
resolution level, in particular those relying on time series analysis (Monnet et al., 2004; Aldeyab 194 
et al., 2008), can be used to focus on the quantification of the selection of antimicrobial resistance 195 
following antimicrobial usage. However, in this type of epidemiological studies, other factors 196 
besides antimicrobial usage (e.g. the clonal spread of resistant strains) will always contribute to 197 
the observed occurrence of antimicrobial resistance. Spatial resolution of studies monitoring 198 
antimicrobial usage trends over time depends on the level of interest and can be low (e.g. using 199 
national-aggregated data to monitor national trends) (Wirtz et al., 2010; Grave et al., 2012) to high 200 
(e.g. using farm-level data to monitor individual usage) (Aarestrup et al., 2010). 201 
Temporal resolution refers to the frequency with which antimicrobial usage data is collected. Many 202 
studies rely on annual antimicrobial usage data, whatever their objectives. However, a limited 203 
number of studies collected monthly data to monitor usage trends in outpatient clinics; this made 204 
it possible to describe the seasonal variability of usage (Achermann et al., 2011; Suda et al., 205 
2014), or the association between antimicrobial usage and resistance using time series analysis 206 
(Monnet et al., 2004). Monthly collection of antimicrobial usage is also routinely implemented in 207 
Denmark for human and veterinary antimicrobial products (DANMAP, 2013) and has been used 208 
to highlight specific events, such as the effect on antimicrobial usage of the introduction of generic 209 
versions of drugs (Chauvin, 2009; Jensen et al., 2010). In animal production, it might sometimes 210 
be advisable to adapt the temporal resolution to the length of a typical production cycle, e.g. six 211 
weeks in broiler production (Persoons et al., 2012) or eight months in veal calf production (Pardon 212 
et al., 2012).  213 
One could also consider the specificity of the study’s target population as a third resolution level 214 
component. Thus in veterinary medicine, the resolution of antimicrobial usage studies increases 215 
from multispecies-aggregated data (European Medicines Agency, 2014), to species-specific data 216 
(e.g. pig production) (Obritzhauser et al., 2011), to production type data (e.g. farrow-to-finish pig 217 
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farms) (Moreno, 2014) and up to age-specific data (e.g. weaner pigs) (DANMAP, 2013). A similar 218 
consideration applies to human antimicrobial usage, where national-aggregated data are 219 
commonly subdivided into age group or hospital and outpatient usage data (ECDC, 2012), with 220 
hospital data possibly further detailed at the hospital unit level (e.g. the intensive care unit or the 221 
neonatal and pediatric unit) (Meyer et al., 2003; Grohskopf et al., 2005). 222 
Comprehensiveness of the data collected 223 
The comprehensiveness of antimicrobial usage measurement refers to the capacity to collect 224 
usage data from all units in the target population, e.g. from all herds or all hospitals in the country 225 
if the study is conducted at farm level or hospital level, respectively. This requirement only applies 226 
to benchmarking studies where every single hospital, outpatient clinic or farm is able to compare 227 
its own antimicrobial usage with its peers’ usage (Meyer et al., 2003; Danish Veterinary and Food 228 
Administration, 2011; Bos et al., 2013). For other purposes, a sufficiently large random sample 229 
from the population should provide representative data for the whole population. However, in this 230 
approach, the sampling is of crucial importance to ensure true representativeness. This type of 231 
study often suffers from the need to rely on the willingness of farmers or hospitals to participate 232 
and on the availability of the information needed, which may result in some kind of selection bias. 233 
It should be noted that a balance exists between resolution and comprehensiveness. Indeed, 234 
although comprehensiveness is quite easily achieved at poor resolution level (e.g. collecting 235 
national sales data from a limited number of market authorisation holders), it becomes more 236 
resource-demanding to be comprehensive at high spatial (e.g. collecting data from every farm, 237 
hospital or outpatient clinic) and temporal (e.g. collecting monthly data) resolution levels. The 238 
Danish Vetstat database collecting monthly antimicrobial usage data from all Danish pig farms 239 
represents a good example where both high resolution and comprehensiveness were achieved 240 
(Jensen et al., 2004). However, the operational costs of such system are substantial; they were 241 
estimated to be approximately 200 000 euros on a yearly routine basis for the Vetstat database 242 
(Danish Ministry of Food, Agriculture and Fisheries, personal communication, 2015). 243 
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Stability over time 244 
Stability means that the measurement of antimicrobial usage is comparable over time; it is mostly 245 
relevant for studies aiming to monitor antimicrobial usage trends over time. Stability is challenged 246 
by several issues. First, treatment practices, e.g. average weight at treatment and treatment 247 
duration tend to change over the years (see for example Chauvin et al. (2008) who described 248 
changes in macrolides usage practices in turkey broilers). In addition, the relative importance of 249 
antimicrobial active substances and their corresponding administration routes is evolving; this 250 
might be because one usage of an active substance has been replaced by another. In France, 251 
for example, animal exposure to antimicrobials decreased by 21.7% via the oral route and 252 
increased by 8.6% via the parenteral route between 2007 and 2012, mostly due to the reduction 253 
in medicated feed usage in livestock (Anses, 2014). Antimicrobial usage was also described as 254 
varying seasonally (Ferech et al., 2006; Elseviers et al., 2007), partly following influenza activity 255 
(Coenen et al., 2014). In addition, certain characteristics of antimicrobial products themselves are 256 
evolving over time. For example, the amount of active substance per package was shown to 257 
increase over the years (as the number of units per package and the amount of active substance 258 
per unit increased) (Coenen et al., 2014), whereas antimicrobial prices tended to fall following the 259 
introduction of generic antimicrobial products (Hoffman et al., 2007). The impact of population 260 
demographic changes (including their size and structure, e.g. age group or species distribution) 261 
should also be minimised to achieve stability of antimicrobial usage measurement (Kritsotakis 262 
and Gikas, 2006). 263 
Assessment of exposure 264 
The extent to which the quantification of antimicrobial usage is able to assess exposure to 265 
antimicrobials, which in turn will determine the antimicrobial resistance selection pressure 266 
exerted, should also be considered as an important requirement, especially for studies exploring 267 
the association between antimicrobial usage and resistance. At this stage it is still not fully 268 
determined which of the exposure characteristics (e.g. antimicrobial spectrum of the compound 269 
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used, frequency of exposure, duration of exposure, level of dose, route of administration) is most 270 
influential in terms of the selection pressure exerted. Therefore, there is a clear need for a better 271 
understanding of these questions which will subsequently also make it possible to select the most 272 
appropriate exposure measurements to incorporate into the quantification systems. The ESVAC 273 
project proposed that the description of selection pressure should ideally include both the level of 274 
exposure (antimicrobial agent, daily dose administered and numbers of treated individuals) and 275 
the exposure duration (European Medicines Agency, 2013).  276 
Comparability between populations 277 
Comparability of antimicrobial usage measurement represents a major challenge and is a critical 278 
requirement for studies aiming to compare usage between different populations such as different 279 
species, countries, farms, hospitals or outpatient clinics. Indeed, comparability is threatened at 280 
the same time by i) the diversity of available antimicrobial treatments (authorised products, 281 
dosages, amount of active substance per package, recommended doses) (Postma et al., 2015), 282 
ii) the variability of antimicrobial treatment practices between populations (daily dose, weight at 283 
treatment, treatment length, mode of administration, prices), iii) the differences in the population 284 
at risk of being treated (population size and structure, average weight at treatment), and iv) the 285 
choice of the period at risk of being treated (influence of the season or the species’ average 286 
lifespan). 287 
As observed for resolution and comprehensiveness, the combination of measuring detailed 288 
exposure and aiming at good comparability is often difficult: in general, the better the information 289 
on exposure, the worse the comparability of antimicrobial usage between two populations. As an 290 
example, using Danish and Dutch lists of daily doses for pigs gives a correct estimate of exposure 291 
in each country, but impairs the comparability of their antimicrobial usage (Taverne et al., 2015). 292 
Yet, both requirements can be achieved by working within similar target populations (e.g. species, 293 
production types, age groups). This was highlighted by Bondt et al. (2013) who recommended 294 
collecting veterinary antimicrobial usage data at least at species level to be able to compare the 295 
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antimicrobial exposure between different countries using antimicrobial sales data (Bondt et al., 296 
2013).  297 
 298 
How is antimicrobial usage measured?  299 
As mentioned above, antimicrobial usage is quantified using indicators defined as the number of 300 
‘technical’ units of measurement consumed and normalised by the population at risk of being 301 
treated in a defined period (European Medicines Agency, 2013). The term ‘technical’ means that 302 
the units of measurement are not used as traditional units of measurement (e.g. kilograms) to 303 
measure a physical quantity (e.g. weight) directly, but rather as theoretical reference values to 304 
express consumption of antimicrobial agents (European Medicines Agency, 2013). 305 
Direct and indirect access to the technical unit of measurement of antimicrobial usage 306 
The technical units of measurement described in the literature vary substantially; they include the 307 
treatment costs, the number of antimicrobial items (i.e. the number of times an antimicrobial 308 
appears on prescription) (Scottish Antimicrobial Prescribing Group, 2014) or number of packages 309 
used or used daily, the active substance weight, the number of live kilogram-days or individual-310 
days treated (i.e. the product of a given treatment length and a live weight or a number of 311 
individuals respectively), the number of individuals or live weight receiving a full treatment course, 312 
and the number of individuals treated daily (see Figure 1). Technical units located at the top of 313 
Figure 1 are directly accessible; this means that no estimation or approximation is needed to 314 
collect them (i.e. exact data are accessible); others require some standardisation and calculation. 315 
In addition, some technical units describe the used amount very precisely (e.g. weight of active 316 
substance) whereas others are only a remote estimate of the true usage (e.g. medication cost). 317 
At national level, information on the numbers of packages sold can be directly collected from 318 
manufacturers, wholesalers, pharmacies, prescribing doctors and hospitals or reimbursements 319 
(Coenen et al., 2014 ; Bruyndonckx et al., 2014). The corresponding weight of antimicrobial active 320 
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substance can then easily be deducted by multiplying the number of packages by the package 321 
volume and dose (Ministry of Agriculture, Forestry and Fisheries of Japan, 2013; Food and Drug 322 
Administration, 2014; European Medicines Agency, 2014). Data directly obtained from 323 
manufacturers and wholesalers are exhaustive and relatively easily accessible as they rely on 324 
computed data from a limited number of stakeholders. However, it is almost impossible to identify 325 
by whom, when and how the antimicrobial products were used. In veterinary medicine in 326 
particular, a time delay was observed between sales recorded by manufacturers and their actual 327 
usage by farmers (Anses, 2015). In addition, data collected from manufacturers and wholesalers 328 
only provide exact amounts of antimicrobials sold for all animal species together. However, many 329 
veterinary antimicrobial products are licensed for several species and one needs to reallocate the 330 
amounts sold to the different species to allow for a normalisation by the relevant population at 331 
risk. This can be achieved via several approaches, for example asking the market authorisation 332 
holders to provide an estimate of the amount of active substance sold for each species (Anses, 333 
2014), extrapolating from cross-sectional studies at species level (Filippitzi et al., 2014), or simply 334 
reattributing the amounts proportionally to the animal species demographics (Bondt et al., 2013). 335 
However, in all of these approaches, only an approximation of the distribution will be obtained. 336 
The same issue occurs in human medicine when differentiating outpatient from hospital 337 
antimicrobial usage data obtained from wholesalers (Vander Stichele et al., 2004).  338 
At high resolution level, antimicrobial treatment costs can be directly recorded from the hospital 339 
pharmaceutical expenditures (Arnold et al., 2006; Weese, 2006) or from the farm invoices kept 340 
by the farmer and sometimes entered into technical databases (Corrégé et al., 2014). Numbers 341 
of packages can also be directly collected at hospital level using pharmacy stock data (Ansari et 342 
al., 2003; Schwartz et al., 2007) and at farm level, using for example drug-bottle-collection 343 
containers (Dunlop et al., 1998) or farm deliveries (Hémonic et al., 2013). However, collecting a 344 
posteriori farm delivery data might be tedious in the absence of automated data collection 345 
systems. As only individual treatments are prescribed in human medicine, numbers of treated 346 
individuals might also directly be collected from the number of insured individuals in countries 347 
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where insurance systems are in place (Coenen et al., 2014).  348 
In short, a limited number of technical units are directly accessible at national level, namely the 349 
number of packages and corresponding weight of active substance. Other technical units, such 350 
as the treatment costs and the number of treated individuals, can be available at high resolution 351 
level, but because the number of individual hospitals, outpatient clinics or farms is so high it 352 
becomes very resource-demanding to collect these data, especially when comprehensive data 353 
are required. As a consequence, either automated data collection systems (e.g. OsMed in Italy 354 
(Agenzia Italiana Farmaco, 2016), Vetstat in Denmark (Stege et al., 2003), Ab-register in Belgium 355 
(www.registreab.be)) are set up to collect usage data in an automated way at high resolution or 356 
indirect calculations are used to obtain an estimation of the number of technical units based on a 357 
number of assumptions (see Figure 1). 358 
[Insert Figure 1] 359 
Figure 1 gives an overview of different technical units of measurement that can be determined 360 
from the number of antimicrobial packages or items (and corresponding weight of active 361 
substance) in relation to different ways of describing the population at risk of being treated. First, 362 
the number of live kilogram-days treated is estimated by dividing the weight of active substance 363 
by the daily dose which corresponds to the amount of active substance used per kilogram of 364 
individual and per day. The number of individual-days treated is further obtained by dividing the 365 
number of live kilogram-days treated by the weight at treatment. Antimicrobial usage can also be 366 
expressed as a number of individuals (respectively live weight) receiving a full treatment course, 367 
dividing the number of individual-days treated (respectively number of live kilogram-days treated) 368 
by the treatment length. A complete treatment course is a course of a given length and dose and 369 
the product of the antimicrobial daily dose and the treatment length is commonly called the ‘course 370 
dose’ (Resi et al., 2001; European Medicines Agency, 2013). The number of individuals treated 371 
daily is obtained by dividing the number of individual-days by the period at risk of being treated. 372 
This period is generally set at one year, but alternative possibilities exist, e.g. using the length of 373 
the animal production period (Timmerman et al., 2006).  374 
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Measurement unit of the population at risk of being treated  375 
The population at risk of being treated can be considered from two perspectives: i) as a 376 
denominator by which antimicrobial amounts are normalised in order to estimate precisely which 377 
proportion of the population is exposed to antimicrobials, and ii) as a variable to correct for 378 
fluctuations and differences in population demographics and thus to ensure that the measure is 379 
repeatable over time and comparable between populations (e.g. countries). The population at risk 380 
of being treated is currently expressed using two types of unit: the biomass (or live weight) at risk 381 
of being treated and the number of individuals at risk of being treated. The biomass at risk of 382 
being treated is usually approximated by the product of the number of individuals at risk of being 383 
treated and a standard body weight, the latter being either a standard weight at treatment (ECDC, 384 
EFSA and EMA, 2015) or a standard weight of live and slaughtered animals (Anses, 2014). The 385 
main advantage of using biomass is that it allows different animal species to be combined within 386 
the same population; this is the approach used by the ESVAC project to compute the Population 387 
Correction Unit (PCU) (European Medicines Agency, 2014). In Denmark, where antimicrobial 388 
usage is collected per species and age group, the biomass of a species is calculated by taking 389 
into account the average live body-weight and the average life-span of the species (DANMAP, 390 
2013). An important limitation of the biomass concept is the question whether biomass expressed 391 
as kg of live weight is a good representation of the actual biomass of concern (microflora) over 392 
all species. Therefore it can be concluded that biomass, especially when consisting of a 393 
combination of different species, is only a very rough estimate of the population at risk of being 394 
treated.  395 
The number of individuals at risk of being treated varies with the study resolution level. In 396 
veterinary medicine, this number usually includes both reproductive (also called present or live) 397 
and growing (or slaughtered) animals (Anses, 2013;  NETHMAP and MARAN, 2013) and can be 398 
corrected for export and import of live animals (European Medicines Agency, 2014). Some studies 399 
conducted at farm level only focused on growing animals (Timmerman et al., 2006; Pardon et al., 400 
2012). The definition of animal groups (age categories in particular), which can be based on 401 
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population or herd level data, also influences the number of individuals at risk of being treated. In 402 
human medicine, the sources used to inform the number of individuals at risk of being treated are 403 
related to the specificity of the target population in which antimicrobial usage is measured. Thus, 404 
the number of inhabitants, insured individuals and physician contacts were mostly used to 405 
measure outpatient antimicrobial usage (Coenen et al., 2014), whereas the number of occupied 406 
beds (World Health Organization, 2015a), number of finished consultant episodes (Curtis et al., 407 
2004) or number of admitted patients (Kuster et al., 2008; DANMAP 2013) were proposed to 408 
measure antimicrobial usage at hospital level. However, because the number of occupied beds 409 
is more difficult to collect, some studies also use the number of inhabitants to estimate the 410 
population at risk of being treated in hospital (Vander Stichele et al., 2004).  411 
Data sources 412 
Figure 1 showed that indirect access to the technical units of measurement of antimicrobial usage 413 
requires three parameters to be estimated: the daily dose, the treatment length and the weight of 414 
the animal/patient at treatment. Here we present the sources that can be used to inform these 415 
parameters. 416 
 Data sources to inform daily doses 417 
Daily doses can be presented using standardised international measurement units; in that case, 418 
they are conventionally termed “defined” daily doses (i.e. if national or other values are used, the 419 
term “defined” is omitted). For human antimicrobial usage, the Defined Daily Dose (DDD) was 420 
introduced and defined by WHO as the assumed average maintenance dose per day for a drug 421 
used for its main indication in a 70 kg adult (World Health Organization, 2015a). The principle is 422 
that a single DDD is attributed by Anatomical Therapeutic Chemical (ATC) code (the latter dividing 423 
the antimicrobial active substances into different groups according to the organ or system on 424 
which they act and their therapeutic, pharmacological and chemical properties) (World Health 425 
Organization, 2015a) based on a compromise of the available information including the dose 426 
recommended in the summary of product characteristics (SPC) from various countries. The DDD 427 
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is expressed in milligram per day (the weight at treatment being set at 70 kg), thus the division of 428 
the active substance weight by the DDD directly provides a number of individual-days treated 429 
(see Figure 1). A similar definition was developed for veterinary products (Jensen et al., 2004) 430 
and called Defined Daily Dose for Animals (DDDvet) (European Medicines Agency, 2015) or 431 
DADD (DANMAP, 2013) or ADDkg (Anses, 2014) or daily dosages (dd) (NETHMAP and MARAN, 432 
2013); it is expressed in milligram per kilogram and per day. To our knowledge, no international 433 
list of DDDvet has been developed so far, but several countries have created their own lists 434 
(Anses, 2014; DANMAP, 2013; NETHMAP, 2013). Some discrepancies exist between their 435 
respective methodologies; for example, certain countries compute daily doses for animals per 436 
licensed product and per animal species (Anses, 2014; NETHMAP 2013), whereas others have 437 
developed daily doses for animals listed by active substance, administration route, animal species 438 
and age group (DANMAP, 2013). Moreover, where a range of doses is recommended in the SPC, 439 
some countries work with median values (Jensen et al., 2004), and others with averages (Postma 440 
et al., 2015), maximum values (Anses, 2014) or doses of the main indication (DANMAP, 2013; 441 
World Health Organization, 2015a). Another difficulty relates to the definition of daily doses for 442 
combined products, with the possibility of counting the combination either as one defined daily 443 
dose, regardless of the number of active substances included in the combination (World Health 444 
Organization, 2015a), or as the sum of several defined daily doses corresponding to the number 445 
of combined active substances (usually two or three). When the sum of defined daily doses is 446 
considered, the individual defined daily doses are either the same as those assigned to the single 447 
active substance for the same species or a different one (accounting for synergies between 448 
combined active substances) (European Medicines Agency, 2015). The ESVAC project is 449 
currently developing a common, standardised list of DDDvet across all EU Member States, with 450 
priority being given to broiler, cattle and pig antimicrobial products (European Medicines Agency, 451 
2015). A first attempt to develop such a list for pig products was conducted among four European 452 
countries (Postma et al., 2015) and clearly showed that huge discrepancies in recommended 453 
doses may exist within and between countries for drugs containing the same active substance. 454 
This was confirmed by a recent study that highlighted major differences between daily doses for 455 
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pigs in the Netherlands and in Denmark (Taverne et al., 2015), leading to significant variations in 456 
estimates of antimicrobial consumption in pigs in the Netherlands in 2012. Depending on farm 457 
types and antimicrobial classes, the usage based on Danish daily doses for animals varied from 458 
55.6% to 171.0% of the usage estimated with Dutch daily doses. Similarly in human medicine, 459 
WHO has clearly stated that the DDD is a compromise based on available information about 460 
doses used in various countries (World Health Organization, 2015a). This shows that using DDD 461 
or DDDvet values implies a generalisation which may sometimes be unwanted. This can partially 462 
be avoided through approximating daily doses using the prescribed daily dose or the used daily 463 
dose (i.e. the dose actually administered). Different studies in human and veterinary medicine 464 
showed that both the prescribed daily doses (Chauvin et al., 2002; Jensen et al., 2004; de With, 465 
2009; European Medicines Agency, 2015) and the used daily doses (UDDvet) (Polk et al., 2007; 466 
Callens et al., 2012; Pardon et al., 2012; Persoons et al., 2012; Merle et al., 2014) deviate from 467 
the defined daily doses. Where the used daily dose or the prescribed daily dose is lower than the 468 
defined daily dose, a calculation based on the defined daily dose will underestimate the number 469 
of live kilogram-days treated, the number of individual-days treated, the live weight and the 470 
number of individuals receiving a full treatment course as well as the number of individuals treated 471 
daily (see Figure 1), and will thus underestimate the antimicrobial usage (Polk et al., 2007; Dalton 472 
et al., 2007).  473 
Data sources to inform treatment length 474 
In the same way, treatment length can be estimated from i) the recommended length as defined 475 
in the SPC; this source is used to compute the Defined Course Dose for Animals (DCDvet) which 476 
is the product of the recommended treatment length and the DDDvet (European Medicines 477 
Agency, 2013); the course dose animal is also called ACDkg in France (Anses, 2013), ii) the 478 
prescribed treatment length if available, and iii) the administered treatment length as described 479 
by the medical doctor, the veterinarian, the farmer or the patient himself/herself (Timmerman et 480 
al., 2006; Laanen et al., 2013). Again, recommended treatment lengths were shown to vary 481 
substantially between countries, for example for oral antimicrobial products used in pig veterinary 482 
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medicine (average variation of 7.5 days) (Postma et al., 2015). Administered treatment length 483 
may also deviate from prescribed or recommended treatment length (Kardas, 2002; Swinkels et 484 
al., 2015). If the actual treatment length is shorter than the recommended one, a calculation based 485 
on the recommended treatment length will underestimate antimicrobial usage when expressed 486 
as a number of individuals or a live weight receiving a full treatment course.  487 
Data sources to inform weights at treatment 488 
Body weights at treatment are hardly available from field studies although some studies 489 
extrapolated them from age at treatment (Chauvin et al., 2005; Timmerman et al., 2006); thus 490 
standard weights are usually used. For human antimicrobial usage, body weight is fixed at 70 kg 491 
with the exception of a few products used exclusively in children (World Health Organization, 492 
2015a). On the contrary, the average animal body weight at treatment varies substantially 493 
between species, production types and age groups. If the actual weight at treatment is lower than 494 
the standard body weight (e.g. if antimicrobials are administered to children of 30 kg), a calculation 495 
based on the standard weight at treatment will underestimate antimicrobial usage when 496 
expressed as a number of individuals-days treated, a number of individuals receiving a full 497 
treatment course or a number of individuals treated daily. 498 
The ESVAC project adopted a list of standardised theoretical body weights at the time most likely 499 
for treatment for each species in order to compute the PCU (European Medicines Agency, 2014). 500 
However, field studies conducted at national level showed that these weights differ significantly 501 
between countries, due to different production (e.g. slaughter weights) and treatment practices 502 
as well as different definitions of the animal age groups or categories. Thus, different standard 503 
weights at treatment are presented in national reports for antimicrobial usage in livestock. For 504 
example, veal calves are estimated to be treated on average at 172 kg in the Netherlands 505 
(NETHMAP and MARAN, 2013), 86 kg in Denmark (Jensen et al., 2004), 70 kg in France (Anses, 506 
2013) and 140 kg in the ESVAC project (European Medicines Agency, 2014). Standard weights 507 
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at treatment can also be defined per production type if antimicrobial usage is monitored at this 508 
resolution level (DANMAP, 2013).  509 
Indicators of human and veterinary antimicrobial usage 510 
Figure 1 shows the units of measurement for the amount of antimicrobial usage (in the numerator) 511 
and the population at risk of being treated (in the denominator) that lead to the calculation of 512 
indicators of antimicrobial usage, as well as the relationships between the indicators. For 513 
simplicity, this study includes only the indicators presented in English or French scientific articles 514 
or national reports and for which the quantification of antimicrobial usage is based on antimicrobial 515 
sales, deliveries and reimbursement data. However, these indicators were developed to be used 516 
within a particular context and two indicators built on the same technical units of measurement 517 
are not necessarily based on the exact same data sources. For example, the indicators called 518 
PID and PIID are both calculated from the number of packages used daily normalised by a 519 
number of individuals at risk of being treated (Coenen et al., 2014), but for the PID the 520 
denominator is the number of inhabitants whereas for the PIID the denominator is the number of 521 
insured individuals. Readers are invited to consult the Appendix Table S2 that provides details of 522 
the indicator calculations, highlighting the numerators and the denominators that were used as 523 
well as the data sources to inform them. 524 
 525 
Comparison of antimicrobial usage indicators 526 
A limited number of studies have compared several indicators applied to the same antimicrobial 527 
usage data in order to achieve the same objective. In human medicine, these included some 528 
studies analysing the influence of the selection of different indicator numerators (Kern et al., 2005; 529 
Muller et al., 2006; Polk et al., 2007; Dalton et al., 2007) and denominators (Curtis et al., 2004; 530 
Filius et al., 2005; Kuster et al., 2008) on the comparison and monitoring of antimicrobial usage 531 
in hospital settings. For example, Muller et al. (2006) showed that the number of individual-days 532 
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treated estimated by the DDD approach at a university hospital overestimated the prescribed 533 
number of treatment days by 40%. Other studies quantified the discrepancies in the estimation of 534 
outpatient antimicrobial usage time trends when working with different numerators and 535 
denominators (Coenen et al., 2014; Bruyndonckx et al., 2014). An example is provided by Coenen 536 
et al. (2014) who explored outpatient antimicrobial usage in Belgium between 2002 and 2009 and 537 
concluded that antimicrobial usage increased when expressed in DDD per 1000 inhabitants per 538 
day and decreased when expressed in packages, treatments and insured individuals per 1000 539 
inhabitants per day. In veterinary medicine, some authors applied several indicators based on 540 
different numerators to the same data in order to compare antimicrobial usage between countries 541 
(Taverne et al., 2015) or farms (Jensen et al., 2004), to monitor usage over time (Chauvin et al., 542 
2008) or to describe discrepancies between used and recommended doses (Persoons et al., 543 
2012). Bondt et al. (2013) investigated the impact of denominator selection when comparing 544 
antimicrobial usage based on sales data between countries (Bondt et al., 2013). They showed 545 
that antimicrobial usage based on total sales data and expressed in mg of active substance per 546 
PCU strongly overestimated the true difference in usage in the Netherlands compared to 547 
Denmark, even though the two countries have similar animal demographics. 548 
To further illustrate the differences in outcomes when using different indicators, each indicator 549 
presented in Figure 1 was applied to a notional antimicrobial usage dataset in fattening pigs and 550 
human medicine. The results are presented in Appendix S3 of the Supporting Information; they 551 
illustrate i) the variability observed in a given indicator calculated from different input data and 552 
parameters and ii) the variability observed in a given antimicrobial usage estimate (i.e. with exact 553 
same input data and parameters) calculated with different indicators. Explaining the difference in 554 
outcome between indicators is easier when indicators are directly related (i.e. when numerators 555 
are connected by a direct arrow in Figure 1). In the Appendix S3 example, the observed 556 
correlations between indicators varied from 0.34 to 0.97 and were especially weak for indicators 557 
based on a number of packages used daily or treatment costs.  558 
 559 
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Suggestions on technical units, indicators and data sources to be 560 
selected in accordance with the study objective 561 
Based on the above described requirements related to the specific study objectives and the 562 
available antimicrobial usage measurement approaches, suggestions on preferred technical units 563 
and data sources are provided (Table 2). 564 
[Insert Table 2] 565 
Suggestions to monitor usage trends over time (Objective 1) 566 
For studies aiming to monitor antimicrobial usage trends over time, data can be collected from 567 
national to local level depending on the relevant spatial resolution level. As comprehensiveness 568 
is not critical, data from a representative sample of the population is sufficient. The key 569 
requirement is stability over time, so attention should be paid to updating antimicrobial usage 570 
parameters: defined daily doses (using the DDD list regularly updated by WHO (World Health 571 
Organization, 2015b)), weight at treatment and treatment duration, as well as the size and 572 
structure of the population at risk of being treated, as these are dynamic and influential (Kritsotakis 573 
and Gikas, 2006; Chauvin et al., 2008). Technical units based on number of daily doses (i.e. 574 
number of live kilogram-days treated, live weight or number of individuals receiving a full treatment 575 
course, number of individual-days treated or number of individuals daily treated) or packages and 576 
items should be preferred, as they correct for possible changes in the relative importance of active 577 
substances and corresponding administration routes. Coenen et al. (2014) also recommended 578 
using number of packages (instead of DDD based indicators) in countries dispensing complete 579 
packages; indeed, number of packages was shown to be a better proxy of antimicrobial 580 
prescribing in case the number of units per package (i.e. the pack size) or the dose per unit was 581 
increasing over time (Coenen et al. 2014). Treatment costs are better avoided as antimicrobial 582 
prices were shown to vary with time; however, treatment costs might be considered for economic 583 
or logistical studies over short time periods, where antimicrobial prices and treatment practices 584 
are assumed to be constant. The period at risk of being treated is preferably set at one year to 585 
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correct for seasonal fluctuation in antimicrobial usage patterns (Ferech et al., 2006; Elseviers et 586 
al., 2007); July–June years should be preferred in human medicine to capture winter peaks of 587 
influenza activity within the same 12-month period (Coenen et al., 2014).  588 
Suggestions to compare usage between species or countries (Objective 2) 589 
To compare antimicrobial usage between species or countries, national level data can be used 590 
and does not need to be comprehensive. Technical units based on the number of daily doses 591 
should be preferred, although the weight of active substance might be acceptable for studies 592 
conducted in specific target populations (e.g. same animal species and production type or same 593 
hospital department), and focusing on the same active substance and administration route. 594 
Parameters should be standardised to be able to compare antimicrobial usage based on the 595 
number of live kilogram-days treated, live weight or number of individuals receiving a full treatment 596 
course, number of individual-days treated or number of individuals treated daily. As differences 597 
in parameters do exist between countries, species, hospitals, outpatient clinics or farms, 598 
standardised values need to be defined by consensus (see Postma et al. (2015) for an example). 599 
Treatment costs or number of packages and items do not correct for daily dose, weight at 600 
treatment and treatment length; thus they should be avoided to compare antimicrobial usage 601 
between two populations for any purposes other than economical or logistical ones. Fixed time 602 
period or length of the animal production period can be used to define the period at risk of being 603 
treated.  604 
Suggestions for benchmarking between hospitals, outpatient clinics or farms (Objective 605 
3) 606 
Similar recommendations can be made for the measurement of antimicrobial usage for 607 
benchmarking between hospitals, outpatient clinics and farms, although, in that case, census data 608 
is required to achieve comprehensiveness. Moreover, antimicrobial usage data should be 609 
collected at farm, hospital or outpatient clinic level as high resolution is critical. Number of live 610 
kilogram-days treated, live weight or number of individuals receiving a full treatment course, 611 
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number of individual-days treated or number of individuals daily treated should be preferred to 612 
quantify the amount of antimicrobials consumed, although treatment costs, weight of active 613 
substance or number of items or packages are acceptable for studies conducted in specific target 614 
populations (and when using the weight of active substance, focusing on the same active 615 
substance and administration route). 616 
Suggestions to study the association between antimicrobial usage and antimicrobial 617 
resistance (Objective 4) 618 
To study the association between antimicrobial usage and antimicrobial resistance, data can be 619 
collected either at national level, which includes both the selection and spread of antimicrobial 620 
resistance (i.e. ecological studies), or at farm, hospital or outpatient clinic level, where the focus 621 
is more on the selection of antimicrobial resistance following antimicrobial usage. The number of 622 
live kilogram-days treated, the number of individual-days treated and the number of individuals 623 
treated daily should be preferred as they take into account the level of exposure and the exposure 624 
duration in accordance with the ESVAC project recommendations (European Medicines Agency, 625 
2013). On the contrary, the live weight or the number of individuals receiving a full treatment 626 
course does not vary with treatment length; these units rather describe whether or not individuals 627 
were exposed, without considering for how long. In addition, the study of the association between 628 
antimicrobial usage and resistance should ideally be based on the used daily dose, the actual 629 
weight at treatment and the actual treatment length in order to obtain an accurate description of 630 
the exposure to antimicrobials. Qualitative data (e.g. administration route, antimicrobial class and 631 
spectrum of activity) should also be collected to refine the description of the selection pressure, 632 
although at this stage, it is still unclear what exposure characteristics mostly influence the 633 
selection pressure exerted. The population at risk of being treated should be selected in 634 
accordance with the population under antimicrobial resistance monitoring. In addition, data should 635 
be collected at high temporal resolution (e.g. monthly or quarterly data) as the time delay between 636 
antimicrobial usage and resistance was shown to be short (i.e. several months) (Monnet et al., 637 
2001). 638 
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 639 
Conclusion 640 
Several objectives can be pursued by antimicrobial usage studies, implying a number of 641 
requirements regarding the way in which antimicrobial usage should be measured. In parallel, a 642 
variety of indicators and approaches to measure antimicrobial usage are currently available and 643 
result in substantial variation in outcomes and sometimes even apparent discrepancies. By 644 
combining study requirements with available approaches to measure antimicrobial usage, we 645 
were able to provide some suggestions on the most appropriate indicators and data sources to 646 
be used for a given study objective.  647 
At this stage, however, it was not possible to identify a single indicator as being the most suitable 648 
for a given objective. This would require a number of data gaps to be addressed, in particular: i) 649 
the defining of gold standards for the evaluation of indicators of antimicrobial usage, including for 650 
example their sensitivity and specificity, ii) the absence of a scientific basis to identify which 651 
parameters better describe antimicrobial selection pressure, and iii) the lack of studies comparing 652 
the application of several indicators to the same antimicrobial usage data.  653 
Additionally, in a context of limited resources, it might be difficult to develop multiple monitoring 654 
systems that would perfectly suit every individual study objective. To tackle this issue, one might 655 
consider i) developing intermediate systems that would imperfectly address a combination of 656 
several objectives, ii) promoting the development of parallel monitoring systems (e.g. public-657 
private partnerships) or iii) developing advanced monitoring systems that could properly address 658 
several objectives, i.e. using automated data collection at high resolution to compute more 659 
accurate indicators; however, these come at a cost.  660 
To conclude, we have shown that some difficulties in measuring antimicrobial usage are common 661 
to human and veterinary medicine, and each discipline could certainly benefit from the experience 662 
gained in the other to improve its methodology and possibly to develop a common approach that 663 
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would support the joint analysis of antimicrobial usage data in humans and animals (ECDC, EFSA 664 
and EMA, 2015). 665 
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Table 1. Requirements for the measurement of antimicrobial usage in accordance with the study objective. 
Study objective Expected outcome Requirements for the measurement of antimicrobial usage 
  
Spatial and temporal 
resolution 
Comprehensiveness Stability over time 
Assessment of exposure 
level and duration 
Comparability between 
populations 
1. Monitoring usage 
trends over time 
Antimicrobial usage in a given population over 
period A in comparison with period B 
Low to high Low High Low Low 
2. Comparison of usage 
between different 
species or countries  
Antimicrobial usage by individual or given biomass 
of species or country A in comparison with species 
or country B over a given period of time 
Low Low Low Low High 
3. Benchmarking 
between hospitals, 
outpatient clinics or 
farms 
Antimicrobial usage by individual or given biomass 
in hospital/medical or veterinary practice/farm A in 
comparison with hospital/medical or veterinary 
practice/farm B over a given period of time 
High High Low Medium High 
4. Study the association 
between  antimicrobial 
usage and antimicrobial 
resistance 
Antimicrobial usage in a population that leads to 
the selection and spread of AMR over a given 
period of time 
Low (if selection and 
spread of resistance are 
considered together) 
High (if focus on 
resistance selection) 
Low Low High Low 
 The requirement levels (i.e. low, medium, high) should be read in columns and aim to rank the relative importance of each requirement across the different study objectives. 
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Table 2. Recommendations for the measurement of antimicrobial usage in accordance with the study objective 
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 Study objective 
 
 
 
1. Monitoring of usage trends over 
time 
 
2. Comparison of usage between 
species or countries 
 
3. Benchmarking between hospitals, 
outpatient clinics or farms 
 
4.  Study the association between 
antimicrobial usage and 
antimicrobial resistance 
Data sources to be used 
Amount of antimicrobials 
(numerator) 
 
Data collected from national to local 
level (farm, hospital or outpatient 
clinic), depending on the resolution 
level of interest 
Data can be collected from a 
population sample  
 
National level data as high 
resolution is not critical 
Data can be collected from a 
population sample as 
comprehensiveness is not critical 
 
Data at farm, hospital or outpatient 
clinic as high resolution is critical 
Census data collection as 
comprehensiveness is critical 
 
 
National level data if both selection 
and spread of antimicrobial 
resistance are considered 
Data at farm, hospital or outpatient 
clinic level if focus on the selection 
of antimicrobial resistance 
Data can be collected from a 
population sample as 
comprehensiveness is not critical 
 
Parameters 
 
 
Used or updated standardised daily 
doses, weights at treatments and 
treatment duration (based on field 
studies) 
 
Standardised daily doses, weights 
at treatments and treatment length  
 
Standardised daily doses, weights 
at treatments and treatment length  
 
Used daily doses, weights at 
treatments and treatment length 
should be used to describe the 
selection pressure 
 
Population at risk of being 
treated (denominator) 
 
 
Correct for changes over time in the 
size and structure of the population 
at risk of being treated   
 
 
Preferably similar and specific 
target populations (animal species, 
production types, medical sector) to 
improve comparability 
 
 
Preferably similar and specific 
target populations (animal species, 
production types, medical sector) to 
improve comparability 
 
 
Preferably similar and specific 
target populations (animal species, 
production types, medical sector) to 
relate antimicrobial usage to 
antimicrobial resistance observed in 
the corresponding population 
Technical unit of antimicrobial 
usage measurement 
(numerator) 
Recommended unit 
 
 
 
Number of live kilogram-days treated, 
live weight or number of individuals 
receiving a full treatment course, 
number of individual-days treated, 
number of individuals treated daily, 
number of packages or items 
 
 
 
Number of live kilogram-days 
treated, live weight or number of 
individuals receiving a full treatment 
course, number of individual-days 
treated, number of individuals 
treated daily 
 
 
 
Number of live kilogram-days 
treated, live weight or number of 
individuals receiving a full treatment 
course, number of individual-days 
treated, number of individuals 
treated daily 
 
 
 
Number of live kilogram-days 
treated, the number of individual-
days treated and the number of 
individuals treated daily 
  
Acceptable unit -* Weight of active substance (if focus 
on a specific target populations, 
active substance and administration 
route) 
 
Treatment costs, weight of active 
substance, number of items or 
packages (if focus on a specific 
target population) 
Live weight or number of individuals 
receiving a full treatment course 
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  *No unit or indicator was considered in this cell.  
Units to be avoided Treatment costs, weight of active 
substance (except if short period 
study where treatment prices and 
treatment practices are assumed to 
be constant) 
Treatment costs (might be 
acceptable for comparison between 
species within the same country), 
number of items or packages 
-* Treatment costs, number of items or 
packages, weight of active 
substance 
 
Population at risk of being 
treated (denominator) 
Recommended unit 
in human medicine 
 
 
Number of individuals at risk of being 
treated 
 
 
Number of individuals at risk of 
being treated 
 
 
Number of individuals at risk of 
being treated 
 
 
Number of individuals at risk of 
being treated 
Recommended unit 
in veterinary medicine 
Biomass at risk of being treated (if 
one or multiple species are included), 
number of individuals at risk of being 
treated (if only one species is 
included) 
Biomass at risk of being treated (if 
one or multiple species are 
included), number of individuals at 
risk of being treated (if only one 
species is included) 
Biomass at risk of being treated (if 
one or multiple species are 
included), number of individuals at 
risk of being treated (if only one 
species is included) 
Biomass at risk of being treated (if 
one or multiple species are 
included), number of individuals at 
risk of being treated (if only one 
species is included) 
Period at risk of being treated Annual data to correct for seasonal 
fluctuations 
From July to June to capture winter 
peaks of influenza within the same 
12-month period 
Fixed time period (e.g. 1 year) or 
based on length of the animal 
production period 
Fixed time period (e.g. 1 year)  Monthly or quarterly data  
Appropriate indicator of 
antimicrobial usage 
(corresponding to the above 
recommended units) 
Recommended indicator 
in human medicine 
 
 
 
 
 
In hospital: DDD/FCE, DDD/100 bed-
day, DDD/100 admitted patients 
 
In outpatient clinics: PID, PIID or  
PCD (in countries dispensing 
complete packages), DDD/1000 
inhabitants per year,  TID, TIID, TCD, 
DID, DIID, DCD 
 
 
 
 
In hospital: DDD/FCE, DDD/100 
bed-day, DDD/100 admitted 
patients 
 
In outpatient clinics: DDD/1000 
inhabitants per year, TID, TIID, TCD 
 
 
 
 
In hospital: DDD/FCE, DDD/100 
bed-day, DDD/100 admitted 
patients 
 
In outpatient clinics: DDD/1000 
inhabitants per year, TID, TIID, 
TCD,  DID, DIID, DCD 
 
 
 
 
In hospital:  
DDD/FCE, DDD/100 bed-day, 
DDD/100 admitted patients  
 
In outpatient clinics: 
DDD/1000 inhabitants/year, DID, 
DIID, DCD 
Recommended  indicator 
in veterinary medicine 
DDDvet/1000 animals/year, 
DCDvet/1000 animals/year, nDDay, 
ALEA, TIUDDvet, DAPD 
DDDvet/1000 animals/year, 
DCDvet/1000 animals/year, nDDay, 
ALEA, TIDDDvet, DAPD 
DDDvet/1000 animals/year, 
DCDvet/1000 animals/year, nDDay, 
ALEA, TIDDDvet, DAPD 
DDDvet/1000 animals/year, nDDay,  
TIUDDvet, DAPD  
 
Acceptable indicator 
in human medicine 
 
-* -* PID, PIID, PCD TID, TIID, TCD 
Acceptable indicator 
in veterinary medicine 
 
-* Amount of active substance/1000 
animals/year, amount of active 
substance per PCU 
Treatment cost/kg carcass, amount 
of active substance/1000 
animals/year, amount of active 
substance per PCU 
DCDvet/1000 animals/year, ALEA 
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Fig. 1. Technical units of measurement indirectly accessed from number of packages or items and corresponding indicators of antimicrobial usage in humans and animals 
The white boxes describe the technical units of measurement of antimicrobial usage with the solid arrows representing the calculation steps between them. The grey boxes describe the unit of measurement of the population 
at risk of being treated. Dashed arrows represent the normalisation of the technical unit of measurement by the population at risk of being treated that leads to the different indicators of antimicrobial usage (in bold). 
Underlined (respectively non-underlined) indicators are those used in human (respectively veterinary) medicine. DDD= Defined Daily Dose; DDDvet= Defined Daily Dose for Animals; DCDvet= Defined Course Dose for 
Animals. Please refer to the Appendix Table S2 for a detailed description of the indicators’ calculation formulas. References accompanying the displayed indicators only provide illustrations of possible applications of the 
indicators and are not intended to be exhaustive. 
  
Number of 
packages or items 
Weight of active 
substance (kg) 
Number of 
individuals 
receiving a full 
treatment course 
Number of live 
kilogram-days 
treated 
Live weight 
receiving a full 
treatment course 
(kg) 
Number of 
individuals at risk 
of being treated 
Biomass at risk of 
being treated (kg) 
x volume (l or kg) x 
dose (mg/l or mg/kg) 
/ daily dose 
(mg/kg/day) 
Number of 
individual-days 
treated 
/weight at treatment 
(kg) 
/ treatment 
length (days) 
/ treatment 
length (days) 
 PID, PIID, PCD (Coenen et al., 2014) 
 Items/1000/day (Scottish Antimicrobial  
Prescribing Group, 2014) 
• TID, TIID, TCD (Coenen et al., 2014) 
• DCDvet/1000 animals/year (European 
Medicines Agency, 2013) 
Amount of active 
substance /PCU 
(European Medicines 
Agency, 2014) 
• DDD/1000 inhabitants/year (World 
Health Organization, 2015a) 
• DDD/FCE (Curtis et al., 2004) 
• DDDvet/1000 animals/year (European 
Medicines Agency, 2013) 
• nDDay (NETHMAP and MARAN, 2013) 
Number of 
individuals treated 
daily 
• DID, DIID, DCD (Coenen et al., 2014) 
• DDD/100 bed-day (World Health 
Organization, 2015a) 
• DDD/100 admitted patients (DANMAP,  2013) 
• TIDDDvet, TIUDDvet (Timmerman et al, 2006) 
• DAPD (DANMAP, 2013) 
Amount of active substance/1000 
animals/year (European Medicines 
Agency, 2013) 
ALEA (Anses, 
2014) 
/ period at risk 
of being 
treated (days) 
Number of 
packages or items 
used daily 
/ period at risk of being 
treated (days) 
Treatment 
costs 
Treatment cost/kg 
carcass (Corrégé et 
al., 2014) 
x unit 
price 
